Multiway sensitivity analysis; 20 000-trial Monte Carlo simulation, 80% CI for three IPC outcomes and cost per DALY averted by ART for HIV in Kenya, Bangladesh and Nigeria
| Outcomes | Kenya | Bangladesh | Nigeria |
|---|---|---|---|
| DALYs averted | 206–407 | 13.1–45.8 | 228–564 |
| Net costs | US$7810–US$79 885 | US$18 566–US$41 473 | US$2241–US$61 448 |
| Net cost per DALY averted (cost-effectiveness) | US$23–US$304 | US$519–US$2547 | US$5–US$208 |
| Cost per DALY averted by ART for HIV | US$883 | US$1046 | US$747 |
ART, antiretroviral therapy; DALY, disability-adjusted life-year; IPC, integrated prevention campaign.